- Conditions
- Periodontal Diseases
- Interventions
- Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2569–2592
of 5,936
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Peri-Implantitis
- Interventions
- Observation
- Other
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Timeline
- 2019 – 2020
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Trichomonas Vaginitis, Bacterial Vaginitis
- Interventions
- Metronidazole 500 mg, Secnidazole 2000 MG
- Drug
- Lead sponsor
- Tulane University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • North Miami, Florida • New Orleans, Louisiana
- Conditions
- Insulin Sensitivity
- Interventions
- Carbohydrate Drink
- Dietary Supplement
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 19 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Anemia, Dialysis-Dependent Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 54
- States / cities
- Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- KQ-791, Placebo
- Drug
- Lead sponsor
- Kaneq Bioscience Limited
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 4
- States / cities
- Tempe, Arizona • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Diabetes
- Interventions
- HTI-2088, Placebo
- Drug
- Lead sponsor
- Hengrui Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Myelofibrosis
- Interventions
- SAR302503 (TG101348)
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 6
- States / cities
- La Jolla, California • Stanford, California • Boston, Massachusetts + 3 more
- Conditions
- Infant, Premature, Diseases
- Interventions
- Multisensory early oral administration of human milk
- Other
- Lead sponsor
- Loyola University
- Other
- Eligibility
- 23 Weeks to 32 Weeks
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 2
- States / cities
- Maywood, Illinois
- Conditions
- Edentulous Jaw
- Interventions
- TSV dental implant
- Device
- Lead sponsor
- ZimVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 104 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2024
- U.S. locations
- 4
- States / cities
- New Orleans, Louisiana • Ann Arbor, Michigan • Livonia, Michigan + 1 more
- Conditions
- Head and Neck Cancer
- Interventions
- ZD 1839 500mg
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2018
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Schizophrenia
- Interventions
- 10 mg CVL-231 as IR formulation, 30 mg CVL-231 as slow-release MR formulation, 30 mg CVL-231 as medium release MR formulation, 30 mg CVL-231 as fast release MR formulation, 30 mg CVL-231 Target Release, Fasted, 30 mg CVL-231 Target Release, Fed
- Drug
- Lead sponsor
- Cerevel Therapeutics, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Anterior Cruciate Ligament Injuries, Anterior Cruciate Ligament Rupture, Pain, Postoperative
- Interventions
- Tranexamic Acid, Placebo
- Drug
- Lead sponsor
- Dave Bernholt
- Other
- Eligibility
- 14 Years to 25 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 6
- States / cities
- Skokie, Illinois • St Louis, Missouri • Durham, North Carolina + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- CVD908ssb-TXSVN
- Biological
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- filgrastim, carboplatin, topotecan hydrochloride, WBRT
- Biological · Drug · Radiation
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2008
- U.S. locations
- 23
- States / cities
- Scottsdale, Arizona • Washington D.C., District of Columbia • Jacksonville, Florida + 19 more
- Conditions
- Duchenne Muscular Dystrophy, Duchenne, DMD, Neuromuscular Diseases, Muscular Dystrophies
- Interventions
- SAT-3247, Placebo
- Drug
- Lead sponsor
- Satellos Bioscience, Inc.
- Industry
- Eligibility
- 7 Years to 9 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 4 more
- Conditions
- Autoimmune Connective Tissue Disorder, Immune System Diseases
- Interventions
- Anakinra
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pain
- Interventions
- diclofenac potassium oral solution
- Drug
- Lead sponsor
- Depomed
- Industry
- Eligibility
- 2 Years to 12 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 5
- States / cities
- Sheffield, Alabama • Stanford, California • City of Saint Peters, Missouri + 2 more
- Conditions
- Treatment-resistant Depression
- Interventions
- Esketamine, Placebo, Duloxetine (Oral Antidepressant), Escitalopram (Oral antidepressant), Sertraline (Oral Antidepressant), Venlafaxine Extended Release (XR) (Oral Antidepressant)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 236 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Orange, California • San Rafael, California + 7 more
- Conditions
- Mouth, Edentulous
- Interventions
- Complete traditional dentures, Complete CADCAM dentures
- Device
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 99 Years
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma, Mucosal Melanoma of the Head and Neck, Oral Cavity Mucosal Melanoma, Recurrent Melanoma, Stage II Vulvar Cancer AJCC v7, Stage III Vulvar Cancer AJCC v7, Stage IIIA Vulvar Cancer AJCC v7, Stage IIIB Vulvar Cancer AJCC v7, Stage IIIC Vulvar Cancer AJCC v7, Stage IV Oral Cavity Cancer AJCC v6 and v7, Stage IV Vulvar Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Vaginal Carcinoma
- Interventions
- Conventional Surgery, Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Patient Observation, Radiation Therapy
- Procedure · Biological · Other + 1 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure
- Interventions
- Apixaban, Warfarin, LVAD implant
- Drug · Device
- Lead sponsor
- Palak Shah
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Falls Church, Virginia
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Levosimendan
- Drug
- Lead sponsor
- Orion Corporation, Orion Pharma
- Industry
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 227 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • La Jolla, California • Orange, California + 23 more
- Conditions
- Tumor Lysis Syndrome, Cancer, Hyperuricemia
- Interventions
- Rasburicase (SR29142), Allopurinol
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 15
- States / cities
- Berkeley, California • Los Angeles, California • Denver, Colorado + 12 more